Mazón P, Galve E, Gómez J, Gorostidi M, Górriz JL, Mediavilla JD. [Medical expert consensus in AH on the clinical use of triple fixed-dose antihypertensive therapy in Spain].
HIPERTENSION Y RIESGO VASCULAR 2016;
33:133-144. [PMID:
27129628 DOI:
10.1016/j.hipert.2016.03.001]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2016] [Revised: 02/29/2016] [Accepted: 03/08/2016] [Indexed: 01/13/2023]
Abstract
INTRODUCTION
The opinion of experts (different specialties) on the triple fixed-dose antihypertensive therapy in clinical practice may differ.
MATERIALS AND METHODS
Online questionnaire with controversial aspects of the triple therapy answered by panel of experts in hypertension (HT) using two-round modified Delphi method.
RESULTS
The questionnaire was completed by 158 experts: Internal Medicine (49), Nephrology (26), Cardiology (83). Consensus was reached (agreement) on 27/45 items (60%); 7 items showed differences statistically significant. Consensus was reached regarding: Predictive factors in the need for combination therapy and its efficacy vs. increasing the dose of a pretreatment, and advantage of triple therapy (prescription/adherence/cost/pressure control) vs. free combination.
CONCLUSIONS
This consensus provides an overview of the clinical use of triple therapy in moderate-severe and resistant/difficult to control HT.
Collapse